This article refers to:
In the drug evaluation “Sustained release oral fampridine in the treatment of multiple sclerosis” by Kachuck N published in the August 2009 issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2009) 10 (12):2025-2035), on page 2028 the last two sentences in the left column should have read as follows:
However, average percent increases from baseline walking speed of 7.5, 9.7, and 6.9% were observed for the 10, 15 and 20 mg BID Fampridine-SR groups, respectively, compared to a smaller magnitude of change (1.2%) in the placebo group.
The author and publisher sincerely regret any inconvenience that may have been caused.